Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Microb Pathog ; 177: 106049, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36858184

ABSTRACT

The multidrug-resistant Acinetobacter baumannii is an emerging nosocomial pathogen in the healthcare sector. Intrinsic resistance in A. baumannii is a significant problem framing a perfect treatment regimen. Also, this organism showed more resistance towards the carbapenem antibiotics, especially for imipenem and meropenem. The development of carbapenem-resistant Acinetobacter baumannii is mainly due to the alteration or loss of the porin region in the outer membrane. The most well-known porin in Acinetobacter baumannii is CarO (carbapenem-associated outer membrane protein). The CarO protein, which functions as a porin channel for carbapenem inflow, may contribute to carbapenem resistance. The current study identifies a potent drug candidate with a better binding affinity to the carbapenem-resistant outer membrane protein. We investigated the specificity of carbapenems such as imipenem, meropenem, ertapenem, biapenem, doripenem, and fluoroquinolone drugs such as sitafloxacin against the imipenem-resistant CarO protein was demonstrated using the computational approaches molecular docking and dynamic simulation for 50 ns. As a result, the high to low enzyme-ligand complex's binding affinity exhibited a greater binding affinity for ertapenem -7.76 kcal·mol-1 and sitafloxacin -7.75 kcal·mol-1 than biapenem, doripenem, meropenem, and imipenem. The molecular dynamic simulation and the MMPBSA analysis depicted ertapenem -55.431±25.908 kJ/mol and sitafloxacin -47.154 ± 11.052 kJ/mol with better binding affinity and more stability against the imipenem resistant CarO protein when it compared to other antibiotics.


Subject(s)
Acinetobacter baumannii , Imipenem , Imipenem/pharmacology , Acinetobacter baumannii/metabolism , Meropenem/pharmacology , Ertapenem/pharmacology , Ertapenem/metabolism , Molecular Docking Simulation , Doripenem , Porins/genetics , Porins/metabolism , Bacterial Outer Membrane Proteins/metabolism , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/metabolism , Carbapenems/pharmacology , Microbial Sensitivity Tests
2.
Arch Razi Inst ; 77(2): 785-798, 2022 Apr.
Article in English | MEDLINE | ID: mdl-36284955

ABSTRACT

Klebsiella pneumoniae is an opportunistic bacterium that causes many infections, including septicemia, pneumonia, urinary tract infection, and liver abscesses. There are many mechanisms for antibiotic resistance and K. pneumonia is considered a multidrug-resistant pathogen. This study aimed to find the correlation between the susceptibility of K. pneumonia to certain antibiotics with the porin-related resistance and pumps mechanisms. In total, two genes that are responsible for porin formation were considered in the current study OmpK-35gene and OmpK-36 gene, in addition to other four genes (CfiaS, CfiaL, MFS, and MdtK genes) related to an efflux pump mechanism of antibiotic resistance. The bacterial resistance was investigated towards five cephalosporins (Cefazolin, Cefoxitin, Ceftazidime, Ceftriaxone, and Cefepime) and two carbapenems (imipenem and ertapenem). Clinical samples, including blood, swabs, and urine, consisting of 20 specimens for each group, were collected from patients who attended three hospitals in Baghdad. The VITEK-2 system and genetic tests (polymerase chain reaction and sequencing) of bacterial isolates were applied to confirm the diagnosis of K. pneumoniae and detect the antibiotic sensitivity profile. The results showed that 51 (85%) and 15 (25%) of the total 60 isolates had positive results for OmpK-35 and Omp-K36 genes, respectively. The MFS and MdtK genes were observed (70-88.3%) in cephalosporin-resistant isolates of K. pneumoniae. There were no significant variations of bacterial resistance genes of antibiotics within the specimen groups. It was concluded that the bacterial resistance of the selected antibiotics was elevated markedly with the loss of the OmpK-36 gene with a high expression of MFS and MdtK genes and a slight minimal occurrence in the new generation of carbapenems. The best antimicrobial agent was ertapenem with a percentage of 0% of resistance in all bacterial isolates.


Subject(s)
Klebsiella pneumoniae , Porins , Anti-Bacterial Agents/pharmacology , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , beta-Lactamases/genetics , beta-Lactamases/metabolism , Carbapenems/pharmacology , Carbapenems/metabolism , Cefazolin/metabolism , Cefepime/metabolism , Cefoxitin/metabolism , Ceftazidime/metabolism , Ceftriaxone/metabolism , Cephalosporins/metabolism , Drug Resistance, Bacterial , Ertapenem/metabolism , Imipenem/metabolism , Iraq , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/metabolism , Microbial Sensitivity Tests , Porins/genetics , Porins/metabolism , Prevalence , Humans
3.
J Proteomics ; 268: 104715, 2022 09 30.
Article in English | MEDLINE | ID: mdl-36058541

ABSTRACT

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an urgent threat to human health. Major outer membrane proteins (OMPs) porin mutation is one important resistance mechanism of CRKP, and may also affect the inhibition activity of ß-lactam and ß-lactamase inhibitor combinations. The ertapenem-resistant K. pneumoniae strain 2018B120 with major porin mutations was isolated from a clinical patient. Genomic and time-series proteomic analyses were conducted to retrieve the ertapenem-challenged response of 2018B120. The abundance changing of proteins from PTS systems,  ABC transporters, the autoinducer 2 (AI-2) quorum sensing system, and antioxidant systems can be observed. Overexpression of alternative porins was also noticed to balance major porins' defection. These findings added a detailed regulation network in bacterial resistance mechanisms and gave new insights into bypass adaptation mechanisms the porin deficient bacteria adopted under carbapenem antibiotics pressure. SIGNIFICANCE: Outer membrane porins deficiency is an important mechanism of carbapenem resistance in K. pneumoniae. Comprehensive genomic and proteomic profiling of an ertapenem-resistant K. pneumoniae strain 2018B120 gives a detailed systematic regulation network in bacterial resistance mechanisms. Overexpression of alternative porins to balance major porins' defection was noticed, giving new insights into bypass adaptation mechanisms of porin deficient bacteria.


Subject(s)
Klebsiella pneumoniae , Porins , beta-Lactam Resistance , ATP-Binding Cassette Transporters/metabolism , Anti-Bacterial Agents/pharmacology , Antioxidants/metabolism , Bacterial Proteins/metabolism , Carbapenems/metabolism , Carbapenems/pharmacology , Ertapenem/metabolism , Ertapenem/pharmacology , Humans , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/metabolism , Microbial Sensitivity Tests , Porins/genetics , Porins/metabolism , Proteomics/methods , beta-Lactam Resistance/genetics , beta-Lactamase Inhibitors/metabolism , beta-Lactamases/genetics , beta-Lactamases/metabolism , beta-Lactams/metabolism , beta-Lactams/pharmacology
4.
Article in English | MEDLINE | ID: mdl-29866857

ABSTRACT

A multidrug-resistant Klebsiella pneumoniae 1210 isolate with reduced carbapenem susceptibility revealed the presence of a novel plasmid-encoded blaOXA-48-like gene, named blaOXA-519 The 60.7-kb plasmid (pOXA-519) was similar to the IncL-OXA-48 prototypical plasmid except for a ca. 2-kb deletion due to an IS1R insertion. OXA-519 differed from OXA-48 by a Val120Leu substitution, which resulted in an overall reduced ß-lactam-hydrolysis profile, except those for ertapenem and meropenem, which were increased. Thus, detection of OXA-519 producers using biochemical tests that monitor imipenem hydrolysis will be difficult.


Subject(s)
Base Sequence , Klebsiella pneumoniae/genetics , Mutagenesis, Insertional , Plasmids/chemistry , Sequence Deletion , beta-Lactam Resistance/genetics , beta-Lactamases/genetics , Aged, 80 and over , Amino Acid Substitution , Anti-Bacterial Agents/metabolism , Anti-Bacterial Agents/pharmacology , Ertapenem/metabolism , Ertapenem/pharmacology , Humans , Hydrolysis , Imipenem/metabolism , Imipenem/pharmacology , Isoenzymes/genetics , Isoenzymes/metabolism , Klebsiella Infections/drug therapy , Klebsiella Infections/microbiology , Klebsiella pneumoniae/drug effects , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/isolation & purification , Meropenem/metabolism , Meropenem/pharmacology , Microbial Sensitivity Tests , Plasmids/metabolism , beta-Lactamases/metabolism
5.
Indian J Med Microbiol ; 36(4): 569-571, 2018.
Article in English | MEDLINE | ID: mdl-30880708

ABSTRACT

AcrAB-TolC is a tripartite efflux pump system constitutively expressed which functions as an intrinsic-resistant mechanism found to be responsible for conferring resistance towards dyes, detergents and different compounds including various classes of antibiotics. One global regulator belonging to AraC-type regulator family, regulator of antibiotic resistance A (RarA) up-regulates the expression of AcrAB-TolC encoded in Klebsiella pneumoniae, Enterobacter sp. 638, Serratia proteamaculans 568 and Enterobacter cloacae resulting in multidrug-resistant phenotypes. The present work was initiated to find out the transcriptional response of RarA in clinical isolates of Escherichia coli against concentration gradient carbapenem stress. A total of 22 clinical isolates of E. coli and expression level of regulators were analysed via quantitative real-time polymerase chain reaction with and without carbapenem stress. As a result, a strong correlation between the expressional levels of RarA in AcrAB overexpressed isolates of E. coli and elevated expression was observed when exposed under concentration gradient ertapenem stress. The clones containing pRar showed reduction in the zone of inhibition towards carbapenem, indicating the active participation of RarA in AcrAB overexpressed isolates of E. coli conferring resistance towards carbapenems.


Subject(s)
Adenosine Triphosphatases/biosynthesis , Anti-Bacterial Agents/metabolism , Drug Resistance, Bacterial , Ertapenem/metabolism , Escherichia coli Proteins/biosynthesis , Escherichia coli/drug effects , Gene Expression Regulation, Bacterial/drug effects , Transcriptional Activation/drug effects , Disk Diffusion Antimicrobial Tests , Escherichia coli/genetics , Escherichia coli/isolation & purification , Escherichia coli Infections/microbiology , Gene Expression Profiling , Humans , Real-Time Polymerase Chain Reaction
SELECTION OF CITATIONS
SEARCH DETAIL
...